204 related articles for article (PubMed ID: 10098513)
1. Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
Donaldson CJ; Vaughan JM; Corrigan AZ; Fischer WH; Vale WW
Endocrinology; 1999 Apr; 140(4):1760-6. PubMed ID: 10098513
[TBL] [Abstract][Full Text] [Related]
2. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
Leal AM; Takabe K; Wang L; Donaldson CJ; MacConell LA; Bilezikjian LM; Verma IM; Vale W
Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the extracellular ligand-binding domain of the type II activin receptor.
Greenwald J; Le V; Corrigan A; Fischer W; Komives E; Vale W; Choe S
Biochemistry; 1998 Nov; 37(47):16711-8. PubMed ID: 9843440
[TBL] [Abstract][Full Text] [Related]
4. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
Lewis KA; Gray PC; Blount AL; MacConell LA; Wiater E; Bilezikjian LM; Vale W
Nature; 2000 Mar; 404(6776):411-4. PubMed ID: 10746731
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific binding of radiolabeled activin A by activin receptors and follistatin in postimplantation rat and mouse embryos.
Roberts VJ; Bentley CA; Guo Q; Matzuk MM; Woodruff TK
Endocrinology; 1996 Oct; 137(10):4201-9. PubMed ID: 8828478
[TBL] [Abstract][Full Text] [Related]
6. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism.
Xu J; McKeehan K; Matsuzaki K; McKeehan WL
J Biol Chem; 1995 Mar; 270(11):6308-13. PubMed ID: 7890768
[TBL] [Abstract][Full Text] [Related]
7. Identification of a binding site on the type II activin receptor for activin and inhibin.
Gray PC; Greenwald J; Blount AL; Kunitake KS; Donaldson CJ; Choe S; Vale W
J Biol Chem; 2000 Feb; 275(5):3206-12. PubMed ID: 10652306
[TBL] [Abstract][Full Text] [Related]
8. Ovarian regulation of pituitary inhibin subunit and activin receptor type II gene expression: evidence for a nonsteroidal inhibitory substance.
Dalkin AC; Gilrain JT; Marshall JC
Endocrinology; 1994 Sep; 135(3):944-9. PubMed ID: 8070390
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3.
Takumi T; Moustakas A; Lin HY; Lodish HF
Exp Cell Res; 1995 Jan; 216(1):208-14. PubMed ID: 7813622
[TBL] [Abstract][Full Text] [Related]
10. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
Coerver KA; Woodruff TK; Finegold MJ; Mather J; Bradley A; Matzuk MM
Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
[TBL] [Abstract][Full Text] [Related]
11. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity.
Hüsken-Hindi P; Tsuchida K; Park M; Corrigan AZ; Vaughan JM; Vale WW; Fischer WH
J Biol Chem; 1994 Jul; 269(30):19380-4. PubMed ID: 8034704
[TBL] [Abstract][Full Text] [Related]
12. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
Lebrun JJ; Vale WW
Mol Cell Biol; 1997 Mar; 17(3):1682-91. PubMed ID: 9032295
[TBL] [Abstract][Full Text] [Related]
13. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer.
Kleeff J; Ishiwata T; Friess H; Büchler MW; Korc M
Int J Cancer; 1998 Sep; 77(6):860-8. PubMed ID: 9714055
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
[TBL] [Abstract][Full Text] [Related]
15. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.
Greenwald J; Fischer WH; Vale WW; Choe S
Nat Struct Biol; 1999 Jan; 6(1):18-22. PubMed ID: 9886286
[TBL] [Abstract][Full Text] [Related]
16. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins.
Farnworth PG; Wang Y; Leembruggen P; Ooi GT; Harrison C; Robertson DM; Findlay JK
J Endocrinol; 2006 Mar; 188(3):451-65. PubMed ID: 16522726
[TBL] [Abstract][Full Text] [Related]
17. Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle.
Halvorson LM; Weiss J; Bauer-Dantoin AC; Jameson JL
Endocrinology; 1994 Mar; 134(3):1247-53. PubMed ID: 8119165
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
19. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
Yamashita H; ten Dijke P; Huylebroeck D; Sampath TK; Andries M; Smith JC; Heldin CH; Miyazono K
J Cell Biol; 1995 Jul; 130(1):217-26. PubMed ID: 7790373
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial lineages.
Li Q; Karam SM; Coerver KA; Matzuk MM; Gordon JI
Mol Endocrinol; 1998 Feb; 12(2):181-92. PubMed ID: 9482661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
